Research progress of Bruton tyrosine kinase inhibitors in mantle cell lymphoma / 白血病·淋巴瘤

ABSTRACT

Mantle cell lymphoma (MCL), is a disease with high heterogeneity, which is insensitivity to the chemotherapy and presents poor prognosis. Appearance of the Bruton tyrosine kinase (BTK) targeted inhibitors, such as ibrutinib, provides novel treatment strategy for MCL. This review focused on the latest achievements of BTK inhibitors in MCL treatment.